Verkazia Now Available for Vernal Keratoconjunctivitis
Verkazia is an oil-in-water cationic emulsion that works by inhibiting T-cell activation and reducing the level of immune cells and mediators.
Verkazia is an oil-in-water cationic emulsion that works by inhibiting T-cell activation and reducing the level of immune cells and mediators.
Regular users may be at risk for serous retinal detachment, retinal vascular occlusion, and ischemic optic neuropathy
In December 2021, the FDA approved the prescription to OTC switch for Lastacaft.
Acuvue Theravision with Ketotifen reduced ocular itching within 3 minutes and the response was sustained for up to 12 hours after lens insertion.
The approval was based on data from three phase 3 studies that evaluated the efficacy and safety of Dextenza in patients with allergic conjunctivitis.
Difluprednate Ophthalmic Emulsion 0.05% is an AB-rated generic equivalent of Durezol.
The approval was based on data from two randomized, multicenter, double-masked, vehicle-controlled trials that evaluated the efficacy and safety of Verkazia in patients with VKC.
Pataday Once Daily Relief Extra Strength is indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.
Eysuvis (loteprednol etabonate ophthalmic suspension) is now available for the short-term treatment of the signs and symptoms of dry eye disease.
Results from 4 clinical trials showed that treatment with Eysuvis was associated with significant improvements in both the signs and symptoms of dry eye disease.